Heart Device Approval Might Change The Case For Investing In Abbott Stock (ABT)

Simply Wall St.11-09

Abbott Laboratories recently reported new cardiology and oncology data, including FDA approval of the Amplatzer Paraclose PVL Occluder and positive trial results for Amulet 360, SonicForce IVL and the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682823765?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/247483-card/1788988990542","is_english":true,"pubTime":"2026-11-09 00:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682823765","market":"nz","top_or_hot":-1,"title":"Heart Device Approval Might Change The Case For Investing In Abbott Stock (ABT)","media":"Simply Wall St.","content":"<div>\n<p>Abbott Laboratories recently reported new cardiology and oncology data, including FDA approval of the Amplatzer Paraclose PVL Occluder and positive trial results for Amulet 360, SonicForce IVL and the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/heart-device-approval-might-change-the-case-for-investing-in\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heart Device Approval Might Change The Case For Investing In Abbott Stock (ABT)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeart Device Approval Might Change The Case For Investing In Abbott Stock (ABT)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-09 00:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/heart-device-approval-might-change-the-case-for-investing-in><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Abbott Laboratories recently reported new cardiology and oncology data, including FDA approval of the Amplatzer Paraclose PVL Occluder and positive trial results for Amulet 360, SonicForce IVL and the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/heart-device-approval-might-change-the-case-for-investing-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0122379950.USD","symbol_name":"贝莱德世界健康科学A2","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/heart-device-approval-might-change-the-case-for-investing-in","article_id":"2682823765","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/247483-card/1788988990542"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/heart-device-approval-might-change-the-case-for-investing-in","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682823765","pubTimestamp":1794154939,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0122379950.USD":"贝莱德世界健康科学A2","BK4504":"桥水持仓","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4568":"美国抗疫概念","ABT":"雅培","LU0058720904.USD":"联博国际健康护理基金A","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","IHI":"iShares Dow Jones U.S. Medical D","BK4585":"ETF&股票定投概念","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","TMED":"T. Rowe Price Health Care ETF","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4566":"资本集团","ABT.AU":"Abundant Produce","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4082":"医疗保健设备","BK4592":"伊斯兰概念"},"translate_title":"心脏设备批准可能会改变投资雅培股票 (ABT) 的情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PJP":0.6,"IHI":0.6,"ABT.AU":1.5,"ABT":1.5,"TMED":0.6},"content_text":"Abbott Laboratories recently reported new cardiology and oncology data, including FDA approval of the Amplatzer Paraclose PVL Occluder and positive trial results for Amulet 360, SonicForce IVL and the next-generation Oncodetect MRD cancer test. These launches and study readouts point to a heavier emphasis on complex structural heart procedures and ultra-sensitive cancer monitoring. This shift could reshape Abbott Laboratories' product mix, capital needs and regulatory risk profile over time. Attention now turns to how Abbott Laboratories' FDA-cleared Paraclose device and broader cardiology pipeline might influence the longer-term investment narrative.  Scan Abbott Laboratories' cardiology push against a curated peer set to see how other device makers with complex heart portfolios stack up in the list of solid balance sheet and fundamentals (25 results). AdvertisementAbbott Laboratories Investment Narrative Recap To own Abbott Laboratories you need to believe the device, diagnostics and Nutrition engines can offset legal costs, capital spending and a rich P/E. The key short term swing factor is execution in higher acuity devices like structural heart and electrophysiology, which can influence mix, pricing power and how quickly earnings recover from prior margin pressure. The near term risk remains legal and regulatory exposure in Nutrition, plus execution risk as Abbott Laboratories layers new cardiac devices on top of an existing portfolio already facing a Class II recall. Recent cardiology and oncology updates look directionally supportive for the product story, but do not alter that central risk reward tension yet. Among recent headlines, the Amulet 360 VERITAS one year data is most relevant to this cardiology theme. The device posted 96.3% complete left atrial appendage closure on imaging and more than 98% of patients free from ischemic stroke or systemic embolism at one year, reinforcing Abbott Laboratories focus on complex atrial fibrillation related interventions. That performance, together with CE Mark approval and U.S. investigational status, feeds directly into the catalyst of expanding structural heart and electrophysiology procedures. It also highlights the operational trade off. Deeper involvement in high stakes cardiac care can support higher value device usage, while at the same time increasing regulatory oversight, procedural complexity and potential recall or liability exposure. Abbott Laboratories' current analyst narrative points to US$60.0b in revenue and US$9.6b in earnings by 2029, based on 8.8% yearly revenue growth and an earnings increase of about US$4.2b from US$5.4b today. Uncover how Abbott Laboratories' fair value indicates a 9% potential upside to its current price that could narrow quickly. NYSE:ABT 1-Year Stock Price Chart Exploring Other Perspectives Four fair value estimates from the Simply Wall St Community cluster between about US$118.5 and US$151.8, with some members seeing Abbott Laboratories as close to fully priced and others assigning a much richer outlook. Those views sit alongside legal and margin risks in Nutrition and a cardiology pipeline that could alter earnings quality. Investor opinions can differ sharply, so explore several of these community viewpoints before forming your own stance. Explore 3 other Abbott Laboratories fair value estimates, including one that suggests there could be as much as 38% upside from the current price. The Verdict Is Yours Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Abbott Laboratories research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision. See our latest analysis for Abbott Laboratories. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Abbott Laboratories' overall financial health at a glance.  Looking for more investment ideas beyond Abbott Laboratories? If Abbott Laboratories is on your radar, it can help to compare it with other companies that have different risk, income and balance sheet profiles. Use the Simply Wall St Screener to quickly surface ideas that match the kind of portfolio you want to build.  If you are hunting for potential mispricing, review companies flagged in the 38 high quality undervalued stocks to see which ones meet your quality and valuation thresholds. If income stability matters most to you, focus on businesses in the 7 dividend fortresses and check whether their payouts line up with your return goals. If balance sheet strength is your priority, scan the 31 resilient stocks with low risk scores to find candidates with more resilient financial profiles.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682823765","isCrawlerRequest":true}